Optiflow™ Flow Matters

Keeping you up-to-date with emerging nasal high flow (NHF) clinical evidence and practice guidelines. 



Latest edition - use of NHF in Paediatrics

Updated Edition - September 2024

Early use of NHF in infants and children 

In this update we review the literature with the addition of the PARIS 2 trial and provides an evidence-based approach to implementation of NHF in pediatric patients.

Read

 

Previous editions of Flow Matters

An analysis of published studies reveals the equipment most often used to deliver NHF and most used flow rates. 

A review conducted by F&P showed that the flow rates used in the published studies ranged from 10 L/min to 60 L/min, and 84% of the studies required flows ≥ 45 L/min.

Download PDF

ROX Index - a bedside tool for monitoring patients on NHF.

 Author: Stanislav Taktov, M.D., Ph.D.                            The validated ROX index uses just 3 data points to provide an indicator of outcomes in adults with AHRF receiving NHF therapy.

Read online

Download PDF

Subscribe to Flow Matters
If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.

CAPTCHA
By submitting this form, you consent to Fisher & Paykel Healthcare storing your personal information to contact you about your enquiry. Your information will be collected and stored securely by Fisher & Paykel Healthcare Limited based in New Zealand and may be shared with the wider Fisher & Paykel Healthcare group as necessary to support your enquiry. We will not share, disclose or sell your information to third parties for marketing purposes. For full details on how we use and manage your personal information, how long we may retain this information for sales or marketing purposes, your rights to access, correct or delete your personal information, and how to contact us about your personal information, please see our privacy statement.

PM-622804

Part of Close